/Companies

Immuto Scientific

5 known investors

Find your way into Immuto Scientific

Sign up to see every warm intro you have to Immuto Scientific

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Immuto Scientific team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Immuto Scientific uses patient-derived tissue models combined with computational structural proteomics and machine learning to identify disease-specific protein targets for drug discovery. The platform applies advanced mass spectrometry and molecular simulations to distinguish diseased from healthy tissues and accelerate therapeutic development.

Founders & leadership

FAFaraz A Choudhury
Faraz A ChoudhuryCEO & FounderFaraz A Choudhury is the founder and CEO of Immuto Scientific, which uses patient-derived tissue models, computational structural proteomics, and machine learning to identify disease-specific protein targets for drug discovery.
DBDaniel Benjamin
Daniel BenjaminCo-Founder & CTOCo-founder and CTO of Immuto Scientific, which develops patient-derived tissue models and computational approaches to identify protein targets for drug discovery.

Investors · 5

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$1.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$321.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Immuto Scientific do?
Immuto Scientific uses patient-derived tissue models combined with computational structural proteomics and machine learning to identify disease-specific protein targets for drug discovery. The platform applies advanced mass spectrometry and molecular simulations to distinguish diseased from healthy tissues and accelerate therapeutic development.
Who founded Immuto Scientific?
Immuto Scientific was founded by Faraz A Choudhury, Daniel Benjamin.
Who are Immuto Scientific's investors?
Immuto Scientific's investors include DYDX Capital, Great Oaks Venture Capital, Tundra Angels, Venture Management, Wisconsin Investment Partners.